|
Dec 03, 2020
|
BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
|
|
|
Dec 01, 2020
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Nov 30, 2020
|
Allergy Publishes Results from BioCryst’s APeX-J Trial of Oral, Once-Daily Berotralstat for the Prevention of HAE Attacks
|
|
|
Nov 20, 2020
|
BioCryst to Present at Upcoming Virtual Investment Conferences
|
|
|
Nov 13, 2020
|
BioCryst Presents Data Showing Sustained Attack Rate Reductions, Improved Patient Satisfaction and Quality of Life for HAE Patients Taking Berotralstat in APeX-2 Trial
|
|
|
Nov 13, 2020
|
BioCryst Presents New Data Highlighting Burden of Therapy with Current Injectable Prophylaxis Medication for HAE
|
|
|
Nov 12, 2020
|
BioCryst to Present Data at the 2020 ASH Annual Meeting
|
|
|
Nov 05, 2020
|
BioCryst Reports Third Quarter 2020 Financial Results and Upcoming Key Milestones
|
|
|
Nov 02, 2020
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Oct 30, 2020
|
MHRA Grants HAE Patients Early Access to BioCryst’s Berotralstat in United Kingdom
|
|
